Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 12/20 | 1.00 |
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CETP | P11597 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CXCR5 | P32302 | 2/20 | 1.00 |
| ▸ | CCR6 | P51684 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | UBE2N | P61088 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sphingosine SCHEMBL1471985 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| Sphingosine SCHEMBL15650079 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| Sphingosine SCHEMBL22911044 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL22986843 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL21428474 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL22986939 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL20819097 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| Sphingosine SCHEMBL21114357 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| SCHEMBL21428477 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A | |
| Sphingosine SCHEMBL10056604 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11298412-B2 | Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection | Harbins Ruhr Bioscience, Inc. (US) | 2022-04-12 | — | — | US | disclosed |
| WO-2022015348-A1 | SPHINGOID COMPOUNDS FOR USE IN PROPHYLAXIS AND/OR THERAPY OF CORONAVIRIDAE INFECTION | Harbins Ruhr Bioscience, Inc. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-20220016222-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF CORONAVIRIDAE INFECTION | Harbins Ruhr Bioscience, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20200268686-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION | Harbins Ruhr Bioscience, Inc. | 2020-08-27 | — | — | US | disclosed |
| US-10688065-B2 | Sphingoid compounds for prophylaxis and/or therapy of a viral infection | Harbins Ruhr Bioscience, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200113850-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION | Harbins Ruhr Bioscience, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-10294504-B2 | Mutant endoglycoceramidases with enhanced synthetic activity | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2019-05-21 | — | — | US | disclosed |
| US-20160032342-A1 | Mutant Endoglycoceramidases with Enhanced Synthetic Activity | SENEB BIOSCIENCES, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20150258043-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | UNIVERSITY OF DUISBURG-ESSEN (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150258043-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | UNIVERSITY OF DUISBURG-ESSEN (DE) | 2015-09-17 | — | — | US | disclosed |
| US-9068208-B2 | Mutant endoglycoceramidases with enhanced synthetic activity | SENEB BIOSCIENCES, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140147891-A1 | MUTANT ENDOGLYCOCERAMIDASES WITH ENHANCED SYNTHETIC ACTIVITY | The University of British Columbia University- Industry Liaison Office (CA) | 2014-05-29 | — | — | US | disclosed |
| EP-1765998-B1 | MUTANT ENDOGLYCOCERAMIDASES WITH ENHANCED SYNTHETIC ACTIVITY | SENEB BIOSCIENCES INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20090176278-A1 | SOLVENTS FOR MUTANT ENDOGLYCOCERAMIDASES WITH SYNTHETIC ACTIVITY | NEOSE TECHNOLOGIES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090170155-A1 | Mutant Endoglycoceramidases With Enhanced Synthetic Activity | THE UNIVERSITY OF BRITISH COLUMBIA UNIVERSITY-INDU (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090170155-A1 | Mutant Endoglycoceramidases With Enhanced Synthetic Activity | THE UNIVERSITY OF BRITISH COLUMBIA UNIVERSITY-INDU (CA) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268686-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION | SPHK1, SPHK2, S1PR1 | SPHK2 2/4885SPHK1 1/4885MAPT 3657/4885 |
| US-20220016222-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF CORONAVIRIDAE INFECTION | SPHK1, SPHK2, S1PR2 | SPHK2 2/4885SPHK1 1/4885MAPT 2784/4885 |
| US-10688065-B2 | Sphingoid compounds for prophylaxis and/or therapy of a viral infection | SPHK1, SPHK2, S1PR1 | SPHK2 2/4885SPHK1 1/4885MAPT 3657/4885 |
| US-20200113850-A1 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION | SPHK1, SPHK2, S1PR1 | SPHK2 2/4885SPHK1 1/4885MAPT 3657/4885 |
| US-20150258043-A1 | USE OF SPHINGOID LONG CHAIN BASES AND THEIR ANALOGS IN TREATING AND PREVENTING BACTERIAL INFECTIONS | SPTSSB, CFTR, SGMS1 | SPHK2 11/4885SPHK1 9/4885MAPT 4123/4885 |
| US-20090170155-A1 | Mutant Endoglycoceramidases With Enhanced Synthetic Activity | ENGASE, UGCG, GBA1 | SPHK2 292/4885SPHK1 226/4885MAPT 4584/4885 |
| US-11298412-B2 | Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection | SPHK1, SPHK2, S1PR2 | SPHK2 2/4885SPHK1 1/4885MAPT 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.